Manufactured by:Reed Biotech
Save 40%ABMIUM Verified™RUO

NFκB-p52 (Cleaved-A454) Rabbit Polyclonal Antibody

NFκB-p52 (Cleaved-A454) polyclonal antibody; host Rabbit; reactivity Human, Mouse, Rat

SKU:
ABM5032183-1
Manufacturer SKU
RA27789
Product type
Primary Antibodies
TargetNFκB-p52 (Cleaved-A454)
ApplicationsWB, ELISA
Species / reactivityHuman, Mouse, Rat

Manufacturer provenance

Manufactured by:
Reed Biotech
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

disease:A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.,disease:A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).,disease:In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.,domain:The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.,domain:The glycine-rich region (GRR) appears to be a critical element in the generation of p52.,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.,PTM:Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.,PTM:Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.,PTM:While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.,similarity:Contains 1 death domain.,similarity:Contains 1 RHD (Rel-like) domain.,similarity:Contains 7 ANK repeats.,subcellular location:Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).,subunit:Component of the NF-kappa-B RelB-p52 complex. Homodimer; component of the NF-kappa-B p52-p52 complex. Component of the NF-kappa-B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel complex. NFKB2/p52 interacts with NFKBIE. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3.,

Key facts & specifications
Also known as
Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2, H2TF1, Lymphocyte translocation chromosome 10 protein, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Oncogene Lyt-10, Lyt10) [Cleaved into: Nuclear factor NF-kappa-B p52 subunit]
Host species
Rabbit
Clonality
Polyclonal
Dilution range
WB 1:1000-2000 ELISA 1:5000-20000
Immunogen
Synthesized peptide derived from human NFκB-p52 (Cleaved-A454)
Modification
Cleaved-A454
Molecular weight
52 105 kDa
Purification
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Form / buffer
Liquid
Quantity per pack
50 or 100 µL
Validation & performance evidence
ABMIUM Validated™ ABMIUM Verified™ Expected performance Not suitable

Manufacturer-listed application compatibility

Evidence status by application and model.

Species / reactivityWBELISA
Human,Mouse,Rat
Identifiers & database references
Manufacturer SKU
RA27789
Gene ID
4791
UniProt accession
Q00653
Storage, stability & shipping
Storage conditions
-20°C/1 year
Long-term storage
-20°C/1 year
Storage buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Compliance & documents
Datasheet
Open datasheet
Product manual
Open manual
Frequently asked questions
Who manufactured this product?

This product is manufactured by Reed Biotech and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

Reed Biotech
£189.00£113.40